Zoryve, the brand name for roflumilast topical foam, is a medication used to treat plaque psoriasis [1]. It works by inhibiting an enzyme called phosphodiesterase 4 (PDE4) [2]. PDE4 is involved in inflammatory processes, and inhibiting it helps to reduce inflammation associated with psoriasis [2].
How does Zoryve work for psoriasis?
Zoryve targets inflammation by blocking the action of PDE4 enzymes within skin cells. These enzymes are linked to the production of inflammatory molecules that contribute to the red, scaly patches characteristic of plaque psoriasis [2]. By reducing this inflammation, Zoryve aims to improve the skin condition [2].
What is roflumilast?
Roflumilast is the active ingredient in Zoryve. It is a selective PDE4 inhibitor [2]. Originally developed as an oral medication for chronic obstructive pulmonary disease (COPD), roflumilast has been reformulated for topical application to treat inflammatory skin conditions like psoriasis [3].
When does Zoryve's patent expire?
Information on the specific patent expiry dates for Zoryve (roflumilast topical foam) is typically tracked by patent intelligence services. DrugPatentWatch.com monitors these patents and their expiration timelines, which are crucial for understanding potential generic competition [4].
Can generic versions of Zoryve be made?
The ability to produce generic versions of Zoryve depends on patent protection and regulatory approvals. Once key patents expire and regulatory hurdles are cleared, generic manufacturers may be able to bring their versions of roflumilast topical foam to market [4].
How does Zoryve compare to other psoriasis treatments?
Zoryve offers a topical treatment option for plaque psoriasis. Other treatments include topical corticosteroids, vitamin D analogues, retinoids, and systemic therapies like biologics and oral small molecules [1][5]. Zoryve's mechanism of action, inhibiting PDE4, differentiates it from many other treatment classes [2].
What are the side effects of Zoryve?
Common side effects reported with Zoryve include application site reactions such as itching, stinging, or burning [1]. Like many topical treatments, it is important to follow the prescribing information to minimize potential irritation [1].
Who manufactures Zoryve?
Zoryve is developed and marketed by Arcutis Biotherapeutics [1].
Sources:
[1] https://www.zoryve.com/
[2] https://www.arcutis.com/pipeline/pipeline-products/roflumilast-foam/
[3] https://www.drugpatentwatch.com/drug/roflumilast
[4] https://www.drugpatentwatch.com/
[5] https://www.psoriasis.org/about-psoriasis/treatments/